The Global ALK Inhibitors Market is poised to grow at a CAGR of around 19% over the next decade during 2018 to 2026. Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) belonging to the insulin receptor (IR) superfamily. ALK, also known as CD246 is encoded by the ALK gene in humans. Immunohistochemical analysis of adult human tissues uncovers that ALK expression is sparsely scattered in neural cells, endothelial cells and pericytes in the brain.
Factors such as high incidence rates of diseases like lung cancer, increasing drug approvals, and advances in therapeutics are driving the market growth. Though, the side effects associated with the treatment restrain the market growth. Moreover, patient assistance programs and high efficacy of ALK inhibitors in the treatment are opportunities for the ALK inhibitors market.
Based on type, the third-generation anaplastic lymphoma kinase inhibitors segment is going to have a lucrative growth during the forecast period, owing to the good response rates seen in patients with varying treatment history.
The key vendors mentioned are F. Hoffmann-La Roche Ltd, Pfizer Inc, Delenex Therapeutics, Novartis AG, Astellas, Takeda Pharmaceutical Co Ltd, Amgen, Tesaro, Teva, and AstraZeneca.
Key Questions Answered in this Report:
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
Fastest growing markets analysed during the forecast period
Key Topics Covered:
1 Market Synopsis
2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources
3 Market Dynamics
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global ALK Inhibitors Market, By Type
5.2 First-generation Anaplastic Lymphoma Kinase Inhibitors
5.3 Second-generation Anaplastic Lymphoma Kinase Inhibitors
5.4 Third-generation Anaplastic Lymphoma Kinase Inhibitors
6 Global ALK Inhibitors Market, By Distribution Channel
6.2 Online Distribution Channel
6.3 Offline Distribution Channel
7 Global ALK Inhibitors Market, By Geography
7.1 North America
7.3 Asia Pacific
7.4 South America
7.5 Middle East & Africa
8 Strategic Benchmarking
9 Vendors Landscape
9.1 F. Hoffmann-La Roche Ltd.
9.2 Pfizer Inc.
9.3 Delenex Therapeutics
9.4 Novartis AG
9.6 Takeda Pharmaceutical Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/us40bl